Manuel Worcel
About
Manuel Worcel is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Endocrinology, Diabetes and Metabolism.
According to data from OpenAlex, Manuel Worcel has authored 86 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Cardiology and Cardiovascular Medicine, 25 papers in Molecular Biology and 23 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Manuel Worcel's work include Heart Failure Treatment and Management (21 papers), Nitric Oxide and Endothelin Effects (14 papers) and Cardiovascular Function and Risk Factors (13 papers). Manuel Worcel is often cited by papers focused on Heart Failure Treatment and Management (21 papers), Nitric Oxide and Endothelin Effects (14 papers) and Cardiovascular Function and Risk Factors (13 papers). Manuel Worcel collaborates with scholars based in France, United States and Switzerland. Manuel Worcel's co-authors include Jay N. Cohn, Michael L. Sabolinski, Anne L. Taylor, Clyde W. Yancy, Susan Ziesche, S. William Tam, Kirkwood F. Adams, Keith C. Ferdinand, Peter E. Carson and Malcolm P. Taylor and has published in prestigious journals such as Nature, New England Journal of Medicine and Circulation.
In The Last Decade
Manuel Worcel
82 papers receiving 2.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Manuel Worcel France | 26 | 1.7k | 650 | 556 | 353 | 271 | 86 | 3.1k | ||
| Giuseppe A. Sagnella United Kingdom | 35 | 2.4k 1.4× | 848 1.3× | 863 1.6× | 454 1.3× | 387 1.4× | 135 | 4.1k | ||
| Teruo Omae Japan | 33 | 1.9k 1.1× | 586 0.9× | 636 1.1× | 440 1.2× | 618 2.3× | 230 | 4.2k | ||
| James J. Morton United Kingdom | 30 | 1.4k 0.8× | 474 0.7× | 673 1.2× | 692 2.0× | 386 1.4× | 62 | 3.0k | ||
| Graham Macdonald Australia | 24 | 1.5k 0.9× | 230 0.4× | 672 1.2× | 336 1.0× | 500 1.8× | 97 | 3.0k | ||
| J. C. M. Witteman Netherlands | 23 | 1.1k 0.6× | 377 0.6× | 491 0.9× | 483 1.4× | 266 1.0× | 38 | 3.4k | ||
| Felipe Inserra Argentina | 33 | 845 0.5× | 790 1.2× | 626 1.1× | 717 2.0× | 274 1.0× | 88 | 3.1k | ||
| Cristina Sierra Spain | 30 | 980 0.6× | 561 0.9× | 219 0.4× | 295 0.8× | 218 0.8× | 140 | 2.6k | ||
| Keishi Abe Japan | 33 | 2.0k 1.2× | 854 1.3× | 1.1k 2.0× | 510 1.4× | 755 2.8× | 286 | 4.9k | ||
| Walter Ziegler Switzerland | 25 | 588 0.3× | 404 0.6× | 733 1.3× | 291 0.8× | 469 1.7× | 82 | 2.5k | ||
| Yoram Yagil Israel | 28 | 1.3k 0.8× | 957 1.5× | 973 1.8× | 347 1.0× | 412 1.5× | 96 | 3.7k |
Countries citing papers authored by Manuel Worcel
Since
Specialization
Citations
This map shows the geographic impact of Manuel Worcel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuel Worcel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuel Worcel more than expected).
Fields of papers citing papers by Manuel Worcel
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Manuel Worcel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuel Worcel. The network helps show where Manuel Worcel may publish in the future.
Co-authorship network of co-authors of Manuel Worcel
This figure shows the co-authorship network connecting the top 25 collaborators of Manuel Worcel. A scholar is included among the top collaborators of Manuel Worcel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manuel Worcel. Manuel Worcel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
McNamara, Dennis M., Anne L. Taylor, S. William Tam, et al.. (2014). G-Protein Beta-3 Subunit Genotype Predicts Enhanced Benefit of Fixed-Dose Isosorbide Dinitrate and Hydralazine. JACC Heart Failure. 2(6). 551–557.
2.
Sabolinski, Michael L., S. William Tam, Susan Ziesche, et al.. (2012). Effect of Fixed-Dose Combined Isosorbide Dinitrate/Hydralazine in Elderly Patients in the African-American Heart Failure Trial. Journal of Cardiac Failure. 18(8). 600–606.
3.
Mitchell, Judith E., et al.. (2011). Atrial fibrillation and mortality in African American patients with heart failure: Results from the African American Heart Failure Trial (A-HeFT). American Heart Journal. 162(1). 154–159.
4.
Carson, Peter E., S. William Tam, Jalal K. Ghali, et al.. (2009). Relationship of Quality of Life Scores With Baseline Characteristics and Outcomes in the African-American Heart Failure Trial. Journal of Cardiac Failure. 15(10). 835–842.
5.
Ghali, Jalal K., S. William Tam, Michael L. Sabolinski, et al.. (2008). Exploring the Potential Synergistic Action of Spironolactone on Nitric Oxide–Enhancing Therapy: Insights From the African-American Heart Failure Trial. Journal of Cardiac Failure. 14(9). 718–723.
6.
Tam, S. William, Michael L. Sabolinski, Manuel Worcel, Milton Packer, & Jay N. Cohn. (2007). Lack of Bioequivalence between Different Formulations of Isosorbide??Dinitrate and Hydralazine and??the??Fixed-Dose Combination of??Isosorbide Dinitrate/Hydralazine. Clinical Pharmacokinetics. 46(10). 885–895.
7.
Yancy, Clyde W., Jalal K. Ghali, Virginia Braman, et al.. (2007). Evidence for the Continued Safety and Tolerability of Fixed-Dose Isosorbide Dinitrate/Hydralazine in Patients With Chronic Heart Failure (the Extension to African-American Heart Failure Trial). The American Journal of Cardiology. 100(4). 684–689.
8.
Cohn, Jay N., S. William Tam, Inder S. Anand, et al.. (2007). Isosorbide Dinitrate and Hydralazine in a Fixed-Dose Combination Produces Further Regression of Left Ventricular Remodeling in a Well-Treated Black Population With Heart Failure: Results From A-HeFT. Journal of Cardiac Failure. 13(5). 331–339.
9.
Ghali, Jalal K., S. William Tam, Keith C. Ferdinand, et al.. (2007). Effects of ACE Inhibitors or β-Blockers in Patients Treated with the Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine in the African-American Heart Failure Trial. American Journal of Cardiovascular Drugs. 7(5). 373–380.
10.
McNamara, Dennis M., S. William Tam, Michael L. Sabolinski, et al.. (2006). Aldosterone Synthase Promoter Polymorphism Predicts Outcome in African Americans With Heart Failure. Journal of the American College of Cardiology. 48(6). 1277–1282.
11.
Taylor, Anne L., JoAnn Lindenfeld, Susan Ziesche, et al.. (2006). Outcomes by Gender in the African-American Heart Failure Trial. Journal of the American College of Cardiology. 48(11). 2263–2267.
12.
Anand, Inder S., S. William Tam, Thomas S. Rector, et al.. (2006). Influence of Blood Pressure on the Effectiveness of a Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine in the African-American Heart Failure Trial. Journal of the American College of Cardiology. 49(1). 32–39.
13.
Taylor, Anne L., Susan Ziesche, Clyde W. Yancy, et al.. (2004). Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. New England Journal of Medicine. 351(20). 2049–2057.
14.
Meston, Cindy M. & Manuel Worcel. (2002). The Effects of Yohimbine Plus L-arginine Glutamate on Sexual Arousal in Postmenopausal Women with Sexual Arousal Disorder. Archives of Sexual Behavior. 31(4). 323–332.
15.
Lebrét, Thierry, et al.. (2002). Efficacy and Safety of a Novel Combination of L-Arginine Glutamate and Yohimbine Hydrochloride: A New Oral Therapy for Erectile Dysfunction. European Urology. 41(6). 608–613.
16.
Franciosa, Joseph A., Anne L. Taylor, Jay N. Cohn, et al.. (2002). African-American Heart Failure Trial (A-HeFT): Rationale, design, and methodology. Journal of Cardiac Failure. 8(3). 128–135.
17.
Brown, Neil L., et al.. (1988). Angiotensin-converting enzyme inhibition, anti-hypertensive activity and hemodynamic profile of trandolapril (RU 44570). European Journal of Pharmacology. 148(1). 79–91.
18.
Worcel, Manuel, et al.. (1988). Interaction between aldosterone and vasopressin on vascular smooth muscle permeability to sodium. Journal of Steroid Biochemistry. 30(1-6). 477–478.
19.
Jouquey, Simone, et al.. (1988). Structure-activity relationship in PAF-acether. 4. Synthesis and biological activities of carboxylate isosteres. Journal of Medicinal Chemistry. 31(2). 410–415.
20.
Worcel, Manuel, et al.. (1987). Arterial effects of aldosterone and antimineralocorticoid compounds mechanism of action. Journal of Steroid Biochemistry. 27(4-6). 865–869.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Giuseppe A. Sagnella Breakdown of academic impact, for papers by Teruo Omae Breakdown of academic impact, for papers by James J. Morton Breakdown of academic impact, for papers by Graham Macdonald Breakdown of academic impact, for papers by J. C. M. Witteman Breakdown of academic impact, for papers by Felipe Inserra Breakdown of academic impact, for papers by Cristina Sierra Breakdown of academic impact, for papers by Keishi Abe Breakdown of academic impact, for papers by Walter Ziegler Breakdown of academic impact, for papers by Yoram Yagil